Artiva Biotherapeutics, Inc.: 5%+ holders

As of November 10, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Artiva Biotherapeutics, Inc. The largest reported stake is RA Capital Management, L.P.'s, at 37.9%. 8 filings are on record since July 16, 2025 (Schedule 13D/A, July 23, 2026).

Who owns Artiva Biotherapeutics, Inc.?

5AM Ventures VI, L.P. also filed stake reports on 2 other companies ↓

Sell to companies like Artiva Biotherapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-14 · Reporting person: Venrock Healthcare Capital Partners III, L.P. · Sole voting: 0 · Shared voting: 2,043,596 · Sole dispositive: 0 · Shared dispositive: 2,043,596 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-10 · Reporting person: 5AM Ventures VI, L.P. · Sole voting: 0 · Shared voting: 1,171,250 · Sole dispositive: 0 · Shared dispositive: 1,171,250 · SCHEDULE 13G/A, 2026-08-10
• Filing 2026-07-23 · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 18,415,956 · Sole dispositive: 0 · Shared dispositive: 18,415,956 · SCHEDULE 13D/A, 2026-07-23
• Filed 2026-06-15 · Holder: RA Capital Management, L.P. · Percent: 36.6% · SCHEDULE 13D/A
• Filed 2026-05-28 · Holder: GC Corp · Percent: 12.3% · SCHEDULE 13D/A

Artiva Biotherapeutics, Inc. has 8 Schedule 13D or 13G filings on record since 2025-07-16. 3 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Layoffs on record: about 131 jobs, latest 2026-11-09 (layoff filings and notices).

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Artiva Biotherapeutics, Inc. and the warning signs.

See Artiva Biotherapeutics, Inc.'s free Snapshot Watch Artiva Biotherapeutics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Artiva Biotherapeutics, Inc. and the records around it.

Artiva Biotherapeutics, Inc. elsewhere on the record

• Layoff notices Nov 2026
• Who owns it

Companies that share a holder

• 5AM Ventures VI, L.P. also filed stake reports on 2 other companies: CAMP4 THERAPEUTICS CORPORATION (Aug 2026), VOR BIOPHARMA INC. (Jul 2025)
• VIKING GLOBAL INVESTORS LP also filed stake reports on 27 other companies: City Therapeutics, Inc. (Oct 2026), MID AMERICA APARTMENT COMMUNITIES INC. (Oct 2026), REGAL REXNORD CORP (Sep 2026)
• Venrock Healthcare Capital Partners III, L.P. also filed stake reports on 34 other companies: Entera Bio Ltd. (Oct 2026), Lycia Therapeutics, Inc. (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)

Want the whole picture on Artiva Biotherapeutics, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Artiva Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Artiva Biotherapeutics, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   13 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Artiva Biotherapeutics, Inc. by CUSIP 04317A107 and gives its principal executive office as 5505 Morehouse Drive, Suite 100, San Diego, CA 92121 (SCHEDULE 13G/A, 2026-08-14).

What the percentages are based on

Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.Andrew J. Schwab, SCHEDULE 13G/A, 2026-08-10

Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentages of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.Venrock Healthcare Capital Partners III, L.P., SCHEDULE 13G/A, 2026-08-14

Source of funds (Item 3)

Item 3 of the Statement is hereby amended and supplemented as follows: On June 16, 2026, the Fund purchased an aggregate of 124,893 shares of common stock in open market transactions at prices ranging from $8.63 to $9.00 (weighted average sales price of $8.89 per share). On June 25, 2026, the Fund purchased an aggregate of 31,000 shares of common stock in open market transactions at prices ranging from $8.62 to $8.98 (weighted average sales price of $8.88 per share).RA Capital Management, L.P., SCHEDULE 13D/A, 2026-07-23

Timeline

Swipe the table sideways to see every column.

Questions about who owns Artiva Biotherapeutics, Inc.

Who owns Artiva Biotherapeutics, Inc.?

On this page, 3 holders' latest ownership filings report 5% or more of Artiva Biotherapeutics, Inc.: RA Capital Management, L.P. (37.9%, Schedule 13D/A, filed 2026-07-23), GC Corp (12.3%, Schedule 13D/A, filed 2026-05-28) and Viking Global Investors LP (5.4%, Schedule 13G, filed 2026-05-18).

Who are the largest shareholders of Artiva Biotherapeutics, Inc.?

By the share each holder's latest filing reports, the largest holders of Artiva Biotherapeutics, Inc. on this page are RA Capital Management, L.P. (37.9%), GC Corp (12.3%) and Viking Global Investors LP (5.4%).

When did RA Capital Management, L.P. buy into Artiva Biotherapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from RA Capital Management, L.P. on this page is the Schedule 13D/A, filed 2026-05-13, reporting 33.7%; its latest, Schedule 13D/A filed 2026-07-23, reports 37.9%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Artiva Biotherapeutics, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Artiva Biotherapeutics, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Artiva Biotherapeutics, Inc. is mentioned again
• Find former Artiva Biotherapeutics, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes